Give the Federal Trade Commission points for persistence.
For the past 12 years, the agency has been pushing to end what are known in the context of pharmaceutical patent litigation as reverse payment settlements, or pay-for-delay deals. And despite repeated setbacks, the FTC’s objections to these deals—under which brand-name drug companies offer generic rivals cash payments and other forms of compensation to drop patent challenges and delay entry to the market—appear to only have gotten stronger with time.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
